SEC Form 4 · accession 0001019056-17-000550
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott C Stromatt
Officer — Chief Medical Officer and SVP
Period of report
Jun 1, 2017
Accepted (ET)
Jun 1, 2017 · 9:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $2.15 | Jun 1, 2017 | A | 33,700 | A | — | May 31, 2027 | Common Stock | 33,700 | 33,700 | D |
Explanation of responses
- F1The option grant was approved by a committee of Aptevo Therapeutics Inc.'s board of directors on February 22, 2017, subject to stockholder approval of the Amended and Restated 2016 Stock Incentive Plan (the "Plan") under which the option was granted. Aptevo Therapeutics Inc.'s stockholders approved the Plan on May 31, 2017.
- F2The option vests in three equal annual installments beginning on June 1, 2018.